Compare GSK plc (GSK) vs Vanguard Real Estate Index Fund ETF (VNQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Vanguard Real Estate Index Fund ETF — how do they compare? GSK plc trades at $52.72 (market cap $101.34B), while Vanguard Real Estate Index Fund ETF trades at $99.66. The key difference: GSK plc pays a 3.49% dividend while Vanguard Real Estate Index Fund ETF pays none, and Vanguard Real Estate Index Fund ETF is trading nearer its 52-week high, GSK plc nearer its low. Which is the better fit depends on your goals.
| GSK | VNQ | |
|---|---|---|
Market Cap | $101.34B | — |
Sector | Health | — |
52-Week High | $61.18 | $98.66 |
52-Week Low | $36.20 | $87.00 |
Enterprise Value | $121.95B | — |
Dividend Yield | 3.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK's stock trades at $51.25, down 1.99% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 17.78% net margin and 36.42% ROE, supported by a consistent earnings beat history. Recent positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline progress. Valuation appears reasonable with a P/E of 13.71 and EV/EBITDA of 9.16.
The outlook balances a solid core business and promising oncology pipeline against a mixed analyst consensus and near-term cash flow pressures. Key opportunities lie in execution of new drug launches and the upcoming CEO strategy update, while risks include clinical trial setbacks, competitive pressures, and integration of potential acquisitions like Nuvalent.
VNQ (Vanguard Real Estate ETF) trades at $98.865, up 1.33% with a bullish technical signal supported by 16 buy indicators. The ETF has delivered a 12% year-to-date total return through mid-July 2026, though the rally has recently stalled. Technical analysis shows strong bullish momentum in moving averages while oscillators remain neutral. Recent news highlights VNQ's competitive expense ratio and liquidity advantages over peers, with real estate ETFs broadly outperforming the market despite interest rate pressures.
The outlook for VNQ remains positive given real estate sector momentum and AI-driven data center REIT performance, though sensitivity to Treasury yields presents near-term risk. Income investors benefit from the ETF's diversified real estate exposure without landlord responsibilities. Key risks include interest rate volatility and inflation persistence, but the sector shows resilience with REIT-rate correlations weakening as fundamentals improve.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Vanguard Real Estate Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the MSCI US Investable Market Real Estate 25/50 Index, an index made up of stocks of large, mid-size, and small US companies within the real estate sector. The Advisor attempts to replicate the target index by seeking to invest all of its assets in the stocks that make up the index, in order to hold each stock in approximately the same proportion as its weighting in the index. It is non-diversified.
Read more on VNQ →
